MedTrace Logo

Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever

NCT02483260 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-06-27

No results posted yet for this study

Summary

Is ribavirin a therapeutic option for patients with a probable or suspected case of viral hemorrhagic fever?

Conditions

  • Viral Hemorrhagic Fever

Interventions

DRUG

Ribavirin

1. Loading dose, 33 mg/kg (maximum dose: 2.64 g) 2. Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses) 3. Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses).

Sponsors & Collaborators

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • Joshua Hawley-Molloy, MD · Landstahl Regional Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-16
Primary Completion
2027-10-31
Completion
2028-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02483260 on ClinicalTrials.gov